Literature DB >> 4858213

[Inhibition of lactation by N-(D-6-methyl-8-isoergolin-1-yl)-N',N'-diethylurea (VUFB-6638)].

M Ausková, K Rezábek, V Zikán, M Semonský.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4858213     DOI： 10.1007/BF01921682

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


× No keyword cloud information.
  7 in total

1.  Experimental studies on the effect of ergocornine methanesulphonate on the luteotrophic function of the rat pituitary gland.

Authors:  G H ZEILMAKER; R A CARLSEN
Journal:  Acta Endocrinol (Copenh)       Date:  1962-11

2.  Effects of 2-Br- -ergocryptine on plasma prolactin level and milk yield in cows.

Authors:  H Karg; D Schams; V Reinhardt
Journal:  Experientia       Date:  1972-05-15

3.  [Inhibition of lactation in the rat following administration of D-6-methyl-8-ergolin-I-yl-acetic acid-amide tartrate (VUFB-6683)].

Authors:  M Ausková; K Rezábek; M Semonský
Journal:  Arzneimittelforschung       Date:  1973-04

4.  Effects of 2-Br- -ergokryptine on plasma prolactin level during parturition and onset of lactation in cows.

Authors:  D Schams; V Reinhardt; H Karg
Journal:  Experientia       Date:  1972-06-15

5.  Effects of ergocornine on serum prolactin and LH, and on hypothalamic content of PIF and LRF.

Authors:  W Wuttke; E Cassell; J Meites
Journal:  Endocrinology       Date:  1971-03       Impact factor: 4.736

6.  [2-Br-alpha-ergokryptin: influence on fertility and lactation in the rat].

Authors:  E Flückiger; H R Wagner
Journal:  Experientia       Date:  1968-11-15

7.  Inhibition of lactation and prolactin secretion in rats by ergot alkaloids.

Authors:  C J Shaar; J A Clemens
Journal:  Endocrinology       Date:  1972-01       Impact factor: 4.736
  7 in total
  5 in total

1.  Pharmacokinetics and endocrine effects of terguride in healthy subjects.

Authors:  W Krause; H Träger; G Kühne; N Sauerbrey; K J Gräf; R Dorow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetics of oral terguride in patients with a prolactinoma.

Authors:  R Lapka; J Marek; V Rejholec; Z Franc
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man.

Authors:  W Krause; R Dorow; B Nieuweboer; S H Hasan
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey.

Authors:  W Krause; M Hümpel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Jul-Sep       Impact factor: 2.441

5.  Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women.

Authors:  P L Venturini; R Horowski; M Valenzano; S Costantini; V Fasce; F Gorlero; E Rainer; L De Cecco
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.